Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thi Bich Uyen Le
Observed name:
T Le
Institution:
National University Cancer Institute, Singapore
Observed institutions:
Genentech,
National University Cancer Institute, Singapore,
Zhoushan Hospital,
National Cancer Centre Singapore,
National University Health System,
Concordia University
show all 6
ORCID:
0009-0007-5996-4305
Observed ORCIDs:
0009-0007-5996-4305,
0000-0002-6955-4082
OpenAlex ID:
A5031774185
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
2007
·
L R Desnoyers
, R Pai
, et al.
·
Oncogene
·
275
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
2020
·
Hengyu Lu
, Chen Liu
, et al.
·
Oncotarget
·
46
PDF
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
2020
·
Li Ren Kong
, Richard Weijie Ong
, et al.
·
Nature Communications
·
36
PDF
FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
2020
·
Hung Huynh
, Aldo Prawira
, et al.
·
Experimental & Molecular Medicine
·
31
PDF
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
2025
·
Wan-Qin Chong
, Jia-Li Low
, et al.
·
The Lancet Oncology
·
29
Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma
2021
·
David Wai Meng Tai
, Thi Bich Uyen Le
, et al.
·
Hepatology International
·
22
PDF
Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease
2021
·
Cassandra Millet-Boureima
, Stephanie He
, et al.
·
International Journal of Molecular Sciences
·
21
PDF
Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
2020
·
Aldo Prawira
, Thi Bich Uyen Le
, et al.
·
Liver International
·
19
Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
2021
·
Aldo Prawira
, Thi Bich Uyen Le
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
16
PDF
Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
2020
·
Kheng Wei Yeoh
, Aldo Prawira
, et al.
·
Cancers
·
16
PDF
Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
2020
·
Thi Bich Uyen Le
, Thanh Chung Vu
, et al.
·
International Journal of Molecular Sciences
·
15
PDF
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts
2020
·
Anh Tran
, Tong San Koh
, et al.
·
Molecular Imaging and Biology
·
4
[Effect of miR-23b on the malignant phenotype and the sensitivity of lenvatinib in human hepatocellular carcinoma cells].
2021
·
W N Yan
, S B Li
, et al.
·
Zhonghua ganzangbing zazhi
·
3
Supplementary Figure S3 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Data from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Figure S1 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Figure S2 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Figure S4 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Table S3 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Table S2 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Table S1 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Table S4 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
Supplementary Methods S1 from A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas
2026
·
Jia Li Low
, Wan Qin Chong
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
24
Citation count:
553
H-index:
11
I10-index:
11
Year
Topic
Type